Format

Send to

Choose Destination
Best Pract Res Clin Endocrinol Metab. 2013 Oct;27(5):713-23. doi: 10.1016/j.beem.2013.06.004. Epub 2013 Jul 9.

Determination of catecholamines in plasma and urine.

Author information

1
Service de Biomédecine, Laboratoire des Catécholamines et Peptides, University Hospital of Lausanne, 1011 Lausanne, Switzerland. Electronic address: Eric.grouzmann@chuv.ch.

Abstract

For more than 20 years, measurement of catecholamines in plasma and urine in clinical chemistry laboratories has been the cornerstone of the diagnosis of neuroendocrine tumors deriving from the neural crest such as pheochromocytoma (PHEO) and neuroblastoma (NB), and is still used to assess sympathetic stress function in man and animals. Although assay of catecholamines in urine are still considered the biochemical standard for the diagnosis of NB, they have been progressively abandoned for excluding/confirming PHEOs to the advantage of metanephrines (MNs). Nevertheless, catecholamine determinations are still of interest to improve the biochemical diagnosis of PHEO in difficult cases that usually require a clonidine-suppression test, or to establish whether a patient with PHEO secretes high concentrations of catecholamines in addition to metanephrines. The aim of this chapter is to provide an update about the catecholamine assays in plasma and urine and to show the most common pre-analytical and analytical pitfalls associated with their determination.

KEYWORDS:

catecholamines; dopamine; epinephrine; metanephrines; neuroblastoma; norepinephrine; pheochromocytoma

PMID:
24094641
DOI:
10.1016/j.beem.2013.06.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center